Skip to main
NKTX

Nkarta, Inc. (NKTX) Stock Forecast & Price Target

Nkarta, Inc. (NKTX) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Nkarta is showing positive progress in their clinical trials through an increased number of patient enrollments and potential data release in late 2026, which could further de-risk the company's technology. Their unique approach to developing allogeneic NK cell therapies, combined with collaboration opportunities and a strong management team, puts them in a favorable position for success in the competitive biotech landscape. While risks exist, including safety concerns and financing requirements, Nkarta's strong potential for value creation through their platform technology is reflected in their current Buy rating and $14 price target, supported by a discounted cash flow analysis.

Bears say

Nkarta is a clinical-stage biopharmaceutical company with a negative outlook due to the challenges ahead in the form of regulatory approval, the early stage of their clinical programs, and the uncertain success of their drug candidates. Additionally, the high operating expenses and cash burn rate are cause for concern. Despite a potential quick to market strategy, the data from NTrust-1 and NTrust-2 trials may not be enough to fully understand the efficacy and durability of NKX019. Due to these factors, the outlook for Nkarta's stock is negative.

Nkarta, Inc. (NKTX) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Nkarta, Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Nkarta, Inc. (NKTX) Forecast

Analysts have given Nkarta, Inc. (NKTX) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Nkarta, Inc. (NKTX) has a Strong Buy consensus rating as of Aug 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $11.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $11.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Nkarta, Inc. (NKTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.